Oxidative stress involvement in alpha-synuclein oligomerization in Parkinson's disease cybrids

Antioxidants & Redox Signaling
A Raquel F EstevesSandra M Cardoso

Abstract

Mitochondrial dysfunction, oxidative stress, and alpha-synuclein oligomerization occur in Parkinson disease (PD). We used an in vitro PD cybrid approach that models these three phenomena specifically to evaluate the impact of mitochondria-derived oxidative stress on alpha-synuclein oligomerization. Compared with control cybrid cell lines, reactive oxygen species (ROS) production and protein oxidative stress markers were elevated in PD cybrids. The antioxidants CoQ(10) and GSH attenuated changes in PD cybrid peroxide, protein carbonyl, and protein sulfhydryl levels. Elevated PD cybrid alpha-synuclein oligomer levels were also attenuated by CoQ(10) and GSH. In PD cybrids, alpha-synuclein oligomerization was activated via a complex I-mediated increase in the free tubulin/polymerized tubulin ratio. CoQ(10) but not GSH increased complex I activity, restored ATP to control levels, and normalized the PD cybrid free tubulin/polymerized tubulin ratio. Overall, we conclude that two different antioxidants can decrease alpha-synuclein oligomerization whether by improving mitochondrial function or by preventing protein carbonylation or both. We conclude that mitochondrial dysfunction can induce alpha-synuclein oligomerization via ATP deplet...Continue Reading

References

Mar 1, 1990·Journal of Neurochemistry·A H SchapiraC D Marsden
Sep 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·J MårtenssonA Meister
Feb 1, 1989·Journal of Neurochemistry·D T DexterC D Marsden
Dec 1, 1984·Archives of Biochemistry and Biophysics·D Di MonteS Orrenius
Jan 1, 1994·Methods in Enzymology·R L LevineE Shacter
Mar 1, 1996·Journal of Neuropathology and Experimental Neurology·L S Forno
Oct 1, 1996·Annals of Neurology·R H SwerdlowW D Parker
Oct 27, 1997·Neurology·R H SwerdlowW D Parker
Jan 29, 1999·Archives of Neurology·D J GelbS Gilman
Oct 9, 1999·The American Journal of Pathology·D W DicksonS H Yen
Aug 10, 2000·European Journal of Biochemistry·J B SchulzJ Dichgans
Nov 8, 2001·The Journal of Biological Chemistry·Muhammad Abdul AlimKenji Ueda
Jun 12, 2002·Free Radical Biology & Medicine·Benoit I GiassonJohn Q Trojanowski
Feb 6, 2004·Journal of Neurochemistry·Patricia A TrimmerW Davis Parker
May 14, 2004·Journal of the Neurological Sciences·Kirstin Winkler-StuckWolfram S Kunz
Jun 11, 2004·Journal of Neurochemistry·Sandra M CardosoCatarina R Oliveira
May 5, 2005·Experimental Neurology·Andreas Hald, Julie Lotharius
Aug 17, 2005·Current Drug Targets. CNS and Neurological Disorders·S M CardosoC R Oliveira
Jan 29, 2008·CNS & Neurological Disorders Drug Targets·A NunomuraG Perry
Jul 16, 2008·Free Radical Biology & Medicine·Ana F DominguesSandra M Cardoso

❮ Previous
Next ❯

Citations

Mar 22, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Marina S GorbatyukOleg S Gorbatyuk
Jan 19, 2011·The Journal of Biological Chemistry·Min HuangBeverly S Mitchell
Aug 22, 2008·Antioxidants & Redox Signaling·Daniel A Linseman
Apr 5, 2011·Antioxidants & Redox Signaling·Yuxing ZhangJi Zhang
Jun 12, 2012·Oxidative Medicine and Cellular Longevity·Sonia Gandhi, Andrey Y Abramov
Jun 19, 2009·Molecular Neurodegeneration·Patricia A TrimmerUri Oron
Feb 6, 2009·Molecular Neurodegeneration·Mark R Cookson
Feb 15, 2011·Parkinson's Disease·A R EstevesS M Cardoso
Aug 31, 2011·Journal of Aging Research·Ana-Maria EnciuBogdan O Popescu
Oct 16, 2012·Neurobiology of Disease·David N Hauser, Teresa G Hastings
May 19, 2012·Free Radical Biology & Medicine·María MoránCristina Ugalde
Jul 19, 2011·Mutation Research·Ester López-GallardoEduardo Ruiz-Pesini
Mar 29, 2011·Brain Research Reviews·Christelle En Lin Chua, Bor Luen Tang
Dec 26, 2009·Neurobiology of Disease·A Raquel EstevesSandra M Cardoso
Jun 30, 2009·Experimental Neurology·S M CardosoC R Oliveira
Mar 31, 2009·Experimental Neurology·Patricia A Trimmer, James P Bennett
Oct 31, 2015·Acta Biochimica Et Biophysica Sinica·Tao LiuChuanfang Wu
Jun 27, 2012·Nutritional Neuroscience·Jhon Jairo SutachanGeorge E Barreto
Nov 15, 2014·Molecular Neurobiology·A R EstevesS M Cardoso
Oct 27, 2009·Biochimica Et Biophysica Acta·Paula I MoreiraMark A Smith
Sep 15, 2014·Molecular Neurobiology·Daniel SantosSandra M Cardoso
Oct 15, 2013·Biochimica Et Biophysica Acta·A R EstevesS M Cardoso
May 23, 2012·Mitochondrion·D Santos, S M Cardoso
Aug 28, 2012·Experimental Neurology·Diogo Martins-BrancoSandra M Cardoso
Aug 24, 2016·Frontiers in Molecular Neuroscience·Aida AdlimoghaddamBenedict C Albensi
Mar 3, 2017·Movement Disorders : Official Journal of the Movement Disorder Society·Maria Pia GiannoccaroValerio Carelli
Jan 3, 2018·FEBS Letters·Plamena R Angelova, Andrey Y Abramov
May 8, 2018·Nutrients·Yan Yan JinSeong-Tschool Hong
Dec 23, 2017·GeroScience·Joanna M S DaviesKelvin J A Davies
Oct 19, 2017·Molecular Neurobiology·Claudia ConsalesBarbara Benassi
Dec 3, 2009·Antioxidants & Redox Signaling·Sergio Rosales-CorralGabriela Lopez-Armas
Jun 13, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Richard L JayarajFakhreya Yousuf Jalal
Mar 7, 2020·Biomolecules·Margaux TeilBenjamin Dehay
Aug 14, 2015·The International Journal of Neuroscience·Mohita Shrivastava, Vivekanandhan Subbiah

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.